{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T20:10:21Z","timestamp":1756239021565,"version":"3.44.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1735","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Linvoseltamab (Lynozyfic \u2013 Regeneron), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, has received accelerated approval from the FDA for intravenous treatment of relapsed or refractory multiple myeloma in adults who had received \u22654 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval was based on the response rate and durability of response. Linvoseltamab is the third bispecific BCMA-directed CD3 T-cell engager to be approved for this indication; teclistamab (Tecvayli) and elranatamab (Elrexfio), which are given subcutaneously, were approved earlier.<\/jats:p>","DOI":"10.58347\/tml.2025.1735h","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T19:30:35Z","timestamp":1756236635000},"page":"e136-e137","source":"Crossref","is-referenced-by-count":0,"title":["Linvoseltamab (Lynozyfic) for Multiple Myeloma"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,8,18]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T19:30:35Z","timestamp":1756236635000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1735h"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":0,"journal-issue":{"issue":"1735","published-online":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1735h","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}